Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leukemia

Showing results (311-320 of 13,978) with videos related to

Pageof 1,398
Sort By:
Leukemia|December 17, 2011
Digital gene expression profiling of primary acute lymphoblastic leukemia cellsJ Nordlund, A Kiialainen, O Karlberg, et al.
Leukemia|December 24, 2011
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulationJ M McDaniel, J X Zou, W Fulp, et al.
Leukemia|December 24, 2011
Management of treatment-emergent peripheral neuropathy in multiple myelomaP G Richardson, M Delforge, M Beksac, et al.
Leukemia|March 27, 2012
Natural killer cell immune escape in acute myeloid leukemiaE Lion, Y Willemen, Z N Berneman, et al.
Leukemia|April 2, 2011
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasmsO Abdel-Wahab, A Pardanani, J Patel, et al.
Leukemia|April 2, 2011
Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic casesA W Langerak, F Davi, P Ghia, et al.
Leukemia|July 16, 2011
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidineM T Voso, E Fabiani, A Piciocchi, et al.
Leukemia|July 23, 2011
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomasE Dejean, M H Renalier, M Foisseau, et al.
Leukemia|July 23, 2011
Obesity and the risk of chronic myelogenous leukemia: is this another example of the neoplastic effects of increased body fat?M A Lichtman
Leukemia|June 25, 2011
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroupsS C Lück, A C Russ, U Botzenhardt, et al.
Pageof 1,398

Showing results (311-320 of 13,978) with videos related to

Sort By:
Pageof 1,398
Leukemia|December 17, 2011
Digital gene expression profiling of primary acute lymphoblastic leukemia cellsJ Nordlund, A Kiialainen, O Karlberg, et al.
Leukemia|December 24, 2011
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulationJ M McDaniel, J X Zou, W Fulp, et al.
Leukemia|December 24, 2011
Management of treatment-emergent peripheral neuropathy in multiple myelomaP G Richardson, M Delforge, M Beksac, et al.
Leukemia|March 27, 2012
Natural killer cell immune escape in acute myeloid leukemiaE Lion, Y Willemen, Z N Berneman, et al.
Leukemia|April 2, 2011
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasmsO Abdel-Wahab, A Pardanani, J Patel, et al.
Leukemia|April 2, 2011
Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic casesA W Langerak, F Davi, P Ghia, et al.
Leukemia|July 16, 2011
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidineM T Voso, E Fabiani, A Piciocchi, et al.
Leukemia|July 23, 2011
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomasE Dejean, M H Renalier, M Foisseau, et al.
Leukemia|July 23, 2011
Obesity and the risk of chronic myelogenous leukemia: is this another example of the neoplastic effects of increased body fat?M A Lichtman
Leukemia|June 25, 2011
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroupsS C Lück, A C Russ, U Botzenhardt, et al.
Pageof 1,398